Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 353

1.

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids.

Fuchs CD, Paumgartner G, Mlitz V, Kunczer V, Halilbasic E, Leditznig N, Wahlström A, Ståhlman M, Thüringer A, Kashofer K, Stojakovic T, Marschall HU, Trauner M.

Gut. 2018 Sep;67(9):1683-1691. doi: 10.1136/gutjnl-2017-314553. Epub 2018 Apr 10.

2.

New therapeutic concepts in bile acid transport and signaling for management of cholestasis.

Trauner M, Fuchs CD, Halilbasic E, Paumgartner G.

Hepatology. 2017 Apr;65(4):1393-1404. doi: 10.1002/hep.28991. Epub 2017 Mar 7. Review.

PMID:
27997980
3.

Metabolic preconditioning protects BSEP/ABCB11-/- mice against cholestatic liver injury.

Fuchs CD, Paumgartner G, Wahlström A, Schwabl P, Reiberger T, Leditznig N, Stojakovic T, Rohr-Udilova N, Chiba P, Marschall HU, Trauner M.

J Hepatol. 2017 Jan;66(1):95-101. doi: 10.1016/j.jhep.2016.08.017. Epub 2016 Sep 1.

4.

Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.

Halilbasic E, Fuchs C, Hofer H, Paumgartner G, Trauner M.

Dig Dis. 2015;33 Suppl 2:149-63. doi: 10.1159/000440827. Epub 2015 Dec 7. Review.

PMID:
26641242
5.

Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.

Baghdasaryan A, Fuchs CD, Österreicher CH, Lemberger UJ, Halilbasic E, Påhlman I, Graffner H, Krones E, Fickert P, Wahlström A, Ståhlman M, Paumgartner G, Marschall HU, Trauner M.

J Hepatol. 2016 Mar;64(3):674-81. doi: 10.1016/j.jhep.2015.10.024. Epub 2015 Oct 31.

6.

Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.

Trauner M, Halilbasic E, Claudel T, Steinacher D, Fuchs C, Moustafa T, Pollheimer M, Krones E, Kienbacher C, Traussnigg S, Kazemi-Shirazi L, Munda P, Hofer H, Fickert P, Paumgartner G.

Dig Dis. 2015;33(3):433-9. doi: 10.1159/000371904. Epub 2015 May 27. Review.

PMID:
26045280
7.

The emerging role of transport systems in liver function tests.

Stieger B, Heger M, de Graaf W, Paumgartner G, van Gulik T.

Eur J Pharmacol. 2012 Jan 30;675(1-3):1-5. doi: 10.1016/j.ejphar.2011.11.048. Epub 2011 Dec 6.

8.

Pharmacotherapy of cholestatic liver diseases.

Paumgartner G.

J Dig Dis. 2010 Jun;11(3):119-25. doi: 10.1111/j.1751-2980.2010.00427.x.

PMID:
20579215
9.

Biliary physiology and disease: reflections of a physician-scientist.

Paumgartner G.

Hepatology. 2010 Apr;51(4):1095-106. doi: 10.1002/hep.23472. Review.

PMID:
20373364
10.

Stable expression and functional characterization of a Na+-taurocholate cotransporting green fluorescent protein in human hepatoblastoma HepG2 cells.

Kullak-Ublick GA, Ismair MG, Kubitz R, Schmitt M, Häussinger D, Stieger B, Hagenbuch B, Meier PJ, Beuers U, Paumgartner G.

Cytotechnology. 2000 Oct;34(1-2):1-9. doi: 10.1023/A:1008152729133.

11.

[Short version of the updated S3 (level 3) guidelines for diagnosis and treatment of gallstones of the German Society for Digestive and Metabolic Diseases and the German Society for the Surgery of the Alimentary Tract].

Lammert F, Neubrand MW, Bittner R, Feussner H, Greiner L, Hagenmüller F, Kiehne KH, Ludwig K, Neuhaus H, Paumgartner G, Riemann JF, Sauerbruch T; Deutsche Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS); Deutsche Gesellschaft für Viszeralchirurgie (DGVC).

Dtsch Med Wochenschr. 2008 Feb;133(7):311-6. doi: 10.1055/s-2008-1046712. German.

PMID:
18253923
12.

Medical treatment of cholestatic liver disease.

Paumgartner G, Pusl T.

Clin Liver Dis. 2008 Feb;12(1):53-80, viii. doi: 10.1016/j.cld.2007.11.013. Review.

PMID:
18242497
13.

[S3-guidelines for diagnosis and treatment of gallstones. German Society for Digestive and Metabolic Diseases and German Society for Surgery of the Alimentary Tract].

Lammert F, Neubrand MW, Bittner R, Feussner H, Greiner L, Hagenmüller F, Kiehne KH, Ludwig K, Neuhaus H, Paumgartner G, Riemann JF, Sauerbruch T; Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten; Deutschen Gesellschaft für Viszeralchirurgie zur Diagnostik und Behandlung von Gallensteinen.

Z Gastroenterol. 2007 Sep;45(9):971-1001. German.

PMID:
17874360
14.

Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.

Paumgartner G.

World J Gastroenterol. 2006 Jul 28;12(28):4445-51. Review.

15.

Extracorporeal shock wave lithotripsy of gallstones: 20th anniversary of the first treatment.

Paumgartner G, Sauter GH.

Eur J Gastroenterol Hepatol. 2005 May;17(5):525-7.

PMID:
15827443
16.

Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease.

Paumgartner G, Beuers U.

Clin Liver Dis. 2004 Feb;8(1):67-81, vi. Review.

PMID:
15062194
17.

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodés J, Rosenberg W, Valla D; EASL Jury.

J Hepatol. 2003;39 Suppl 1:S3-25. Review. No abstract available.

PMID:
14708673
18.

Does ursodeoxycholic acid change the proliferation of the colorectal mucosa?. A randomized, placebo-controlled study.

Ochsenkühn T, Marsteller I, Hay U, Diebold J, Paumgartner G, Göke B, Sackmann M.

Digestion. 2003;68(4):209-16. Epub 2003 Dec 30.

PMID:
14707397
19.

Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression.

Paumgartner G.

J Hepatol. 2003 Jul;39(1):112-4. Review. No abstract available.

PMID:
12821052
20.

Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets.

Beuers U, Denk GU, Soroka CJ, Wimmer R, Rust C, Paumgartner G, Boyer JL.

J Biol Chem. 2003 May 16;278(20):17810-8. Epub 2003 Mar 7.

Supplemental Content

Loading ...
Support Center